Actively Recruiting
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)
Led by Loma Linda University · Updated on 2026-02-04
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating oral Nifedipine versus oral Labetalol to see which is better at controlling high blood pressure in women after childbirth. This randomized control trial focuses on postpartum hypertension, a common condition affecting 10% of pregnancies and linked to serious health risks like stroke and heart disease. The study aims to compare these two medications, both considered safe, to determine the best choice for managing high blood pressure after delivery. Participants will receive either oral Nifedipine or oral Labetalol to control their blood pressure. Nifedipine dosing starts at 10mg three times daily and may be increased up to 120mg per day. Labetalol dosing begins at 200mg twice daily with possible increases up to 2400mg per day. Each participant will receive only one of these medications; no experimental drugs or devices are used in this study. During the study, researchers will monitor participants for up to six weeks after delivery, assessing maternal health outcomes including hospital stay length and the need for additional blood pressure medication. Blood pressure readings and maternal complications will be tracked closely. Participants will have regular follow-ups to evaluate medication effects and safety throughout the postpartum period.
CONDITIONS
Brief Title
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female
- Women who develop postpartum hypertension after delivery or have chronic postpartum hypertension requiring medication
- Postpartum hypertension defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg on at least 2 occasions at least 4 hours apart
- Or systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg sustained for more than 15 minutes
- Age 18 years or older
You will not qualify if you...
- History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, or pulmonary edema
- Contraindication to either Nifedipine or Labetalol
- Heart rate less than 60 or greater than 110 beats per minute
- Native language other than English or Spanish
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 weeks following delivery
Participants receive oral nifedipine or oral labetalol to control postpartum hypertension. Dosage may be adjusted based on blood pressure response.
Weekly visits for up to 6 weeks
Trial Site Locations
Total: 1 location
1
Loma Linda University Health
Loma Linda, California, United States, 92350
Actively Recruiting
Research Team
A
Ashra Denise B Tugung, BSc
N
Nikia Gray-Hutto, RN, CCRP
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here